Issue 139. October 2020
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
1 COPYRIGHT STATEMENT This Copy of the Thesis Has Been
University of Plymouth PEARL https://pearl.plymouth.ac.uk 04 University of Plymouth Research Theses 01 Research Theses Main Collection 2012 Life Expansion: Toward an Artistic, Design-Based Theory of the Transhuman / Posthuman Vita-More, Natasha http://hdl.handle.net/10026.1/1182 University of Plymouth All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author. COPYRIGHT STATEMENT This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognize that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the author’s prior consent. 1 Life Expansion: Toward an Artistic, Design-Based Theory of the Transhuman / Posthuman by NATASHA VITA-MORE A thesis submitted to the University of Plymouth in partial fulfillment for the degree of DOCTOR OF PHILOSOPHY School of Art & Media Faculty of Arts April 2012 2 Natasha Vita-More Life Expansion: Toward an Artistic, Design-Based Theory of the Transhuman / Posthuman The thesis’ study of life expansion proposes a framework for artistic, design-based approaches concerned with prolonging human life and sustaining personal identity. To delineate the topic: life expansion means increasing the length of time a person is alive and diversifying the matter in which a person exists. -
Symposium on Aging June 19, 2015 Symposium on Aging the Paul F
The 2015 Harvard / Paul F. Glenn Symposium on Aging June 19, 2015 Symposium on Aging The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Agenda 10th Anniversary Symposium Welcome to the 10th Annual Harvard/Paul F. Glenn Symposium on Aging. June 19, 2015 Each year, the Paul F. Glenn Laboratories host the Harvard Symposium 9:00 - 5:00 on Aging with a mission to present new advances in aging research and to stimulate collaborative research in this area. The symposium has grown over the past 10 years to be one of the biggest events at Harvard Medical School. We have been fortunate to have many of the leaders in the aging field speak 9:00 – 9:45 a.m. Introduction at the symposia and today is no exception. We wish to acknowledge the generosity and vision of Paul F. Glenn, Mark 9:45 – 10:15 a.m. Ensuring the Health of the Germ-line Collins and Leonard Judson for their unwavering support of aging research Cynthia Kenyon, Ph.D. through the Paul F. Glenn Foundation. Thanks to their support, we now have a vibrant community of researchers who study aging and age-related 10:15 – 10:45 a.m. C. elegans Surveillance of Core Cellular diseases. Since the inception of the Paul F. Glenn labs at Harvard in 2005, Components to Detect and Defend Pathogen this network has grown to include aging studies at the Albert Einstein Attacks, and How This Relates to Longevity College of Medicine, the Buck Institute, the Mayo Clinic, Massachusetts Gary Ruvkun, Ph.D. -
Chapter 6: Old People Are People Too, So Let's Act
Career Planning & Adult Development JOURNAL Volume 31, Number 2 ISSN 0736-1920 Summer 2015 OUR FUTURE: Projections of Work and Life Helen Harkness, Guest Editor QThe Future Q The End of Work as We Know It QJobs and Careers on the Front Line of the Future QSilicon Valley and the New Rules of Work Q Training Challenges Facing Education and Training and Career Development in the Future QOld people are people too, so let’s act accordingly Q Crisis of Human Capital in Aerospace: It’s All About the STEM QCollege for All – Reality or Flawed Myth? QOur Jobs: The American Workforce and Economy in Crisis Q The Future Has Arrived: The Future is Now the Present Summer 2015..............................Career Planning and Adult Development JOURNAL..............................1 CAREER PLANNING and ADULT DEVELOPMENT JOURNAL Volume 31, Number 2 ISSN 0736-1920 Summer 2015 OUR FUTURE: Projections of Work and Life Looking Ahead with the Journal,E\Steven E. Beasley, Managing Editor4 Introduction to this Issue, E\ Helen Harkness, PhD, Guest Editor5 Chapter 1: 7KH)XWXUHE\ Leigh Ellen Key8 Chapter 2: 7KH(QGRI:RUNDV:H.QRZ,Wby Andy Hines10 Chapter 3: -REVDQG&DUHHUVRQWKH)URQW/LQHRIWKH)XWXUHby Gary Marx20 Chapter 4: 6LOLFRQ9DOOH\DQGWKH1HZ5XOHVRI:RUNE\Gary A. Bolles28 Chapter 5: 7UDLQLQJ&KDOOHQJHV)DFLQJ(GXFDWLRQDQG7UDLQLQJ DQG&DUHHU'HYHORSPHQWLQWKH)XWXUHE\Timothy C. Mack40 Chapter 6: 2OGSHRSOHDUHSHRSOHWRRVROHW·VDFWDFFRUGLQJO\by Aubrey de Grey47 Chapter 7: &ULVLVRI+XPDQ&DSLWDOLQ$HURVSDFH,W·V$OO$ERXWWKH67(0 by Deborah Westphal51 Chapter 8: &ROOHJHIRU$OO²5HDOLW\RU)ODZHG0\WK"E\ -
Mixing Old and Young: Enhancing Rejuvenation and Accelerating Aging
Mixing old and young: enhancing rejuvenation and accelerating aging Ashley Lau, … , James L. Kirkland, Stefan G. Tullius J Clin Invest. 2019;129(1):4-11. https://doi.org/10.1172/JCI123946. Review Donor age and recipient age are factors that influence transplantation outcomes. Aside from age-associated differences in intrinsic graft function and alloimmune responses, the ability of young and old cells to exert either rejuvenating or aging effects extrinsically may also apply to the transplantation of hematopoietic stem cells or solid organ transplants. While the potential for rejuvenation mediated by the transfer of youthful cells is currently being explored for therapeutic applications, aspects that relate to accelerating aging are no less clinically significant. Those effects may be particularly relevant in transplantation with an age discrepancy between donor and recipient. Here, we review recent advances in understanding the mechanisms by which young and old cells modify their environments to promote rejuvenation- or aging-associated phenotypes. We discuss their relevance to clinical transplantation and highlight potential opportunities for therapeutic intervention. Find the latest version: https://jci.me/123946/pdf REVIEW The Journal of Clinical Investigation Mixing old and young: enhancing rejuvenation and accelerating aging Ashley Lau,1 Brian K. Kennedy,2,3,4,5 James L. Kirkland,6 and Stefan G. Tullius1 1Division of Transplant Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2Departments of Biochemistry and Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 3Singapore Institute for Clinical Sciences, Singapore. 4Agency for Science, Technology and Research (A*STAR), Singapore. -
Who Wants to Live Forever? Reader’S Digest
HEALTH Who Wantsto Live Forever? As a species, we humans appear to be the undisputed masters of our planet. Moreover, since Yuri Gagarin’s inaugural space flight in 1961, we can even leave the confines of Earth to travel in space. Yet, we have one Achilles’ heel—we’re mortal BY CHRIS MENON 1234567890 1234567890 36 BRAIN LIGHT/ALAMY STOCK PHOTO WHO WANTS TO LIVE FOREVER? READEr’s DIGEST T 122 YEARS, THE MAXIMUM HUMAN LIFESPAN lags well behind some species of giant tortoise (188 years), Greenland shark (400 years) and the record set by the lowly Icelandic clam (507 years). Even those relatively few humans who do manage to make it past 100—some 14,570 people in the UK in 2015—are invariably bedeviled byA poor health. Recently, efforts to extend the healthy of Amazon, has similarly invested human lifespan have achieved much in Unity Biotechnology, which aims publicity following the backing of “to design therapeutics that prevent, visionary, super-rich Silicon Valley halt, or reverse diseases of ageing”. tech entrepreneurs. In 2013, Google’s Unity intends to develop a new founders created a subsidiary class of therapies called “senolytic company called Calico (short for medicines”, designed to selectively the California Life Company), eliminate senescent cells. Senescent Billionaire researchers, which promptly hired a team of top cells accumulate with age and, Some believe that death, Arthur Levinson, Jeff technologies that scientists and now has more than unlike normal cells, they secrete like any disease, can be Bezos and Elon Musk the SENS Research £1bn in the bank to fund its work. -
David Sinclair Can Dramatically Extend the Life Span of Yeast
News Focus Lenny Guarente and his former postdoc David Sinclair can dramatically extend the life span of yeast. They’re battling over how this works, and competing head-to-head to grant extra years to humans Aging Research’s Family Feud BOSTON AND CAMBRIDGE,MASSACHUSETTS—At tenure-track spot on Harvard’s faculty in late share many traits common among successful 34, David Sinclair is a rising star. His spa- 1999. He then made clear that his old profes- scientists. Both are deeply ambitious, relent- cious ninth-floor office at Harvard Medical sor’s pet theories weren’t off limits. At a lessly competitive, and supremely self-confi- School boasts a panoramic Boston view. His meeting at Cold Spring Harbor Laboratory dent. Both savor the limelight. Both love sci- rapidly growing lab pulled off the feat of pub- in late 2002, Sinclair surprised Guarente by ence and show little interest in other pursuits. lishing in both Nature and Science last year, challenging him on how a key gene Guarente Still, they’ve retained something of the and it made headlines around the world with discovered extends life in yeast. That sparked parent-child relationship that can shape in- a study of the possible antiaging properties of a bitter dispute that crescendoed this winter, teractions between senior researchers and a molecule found in red wine. In a typical when the pair published dueling papers. their students. Like a father dismayed when day, he fields calls from a couple practicing a Researchers who study aging are finding his son joins a punk rock band, and then dis- radical diet to extend life span, and from an the quarrel both intellectually provocative and mayed further when it attracts devoted fans actor hunting for antiaging pills and the a lively source of gossip. -
Cryonics Magazine, Q1 1999
Mark Your Calendars Today! BioStasis 2000 June of the Year 2000 ave you ever considered Asilomar Conference Center Hwriting for publication? If not, let me warn you that it Northern California can be a masochistic pursuit. The simultaneous advent of the word processor and the onset of the Initial List Post-Literate Era have flooded every market with manuscripts, of Speakers: while severely diluting the aver- age quality of work. Most editors can’t keep up with the tsunami of amateurish submissions washing Eric Drexler, over their desks every day. They don’t have time to strain out the Ph.D. writers with potential, offer them personal advice, and help them to Ralph Merkle, develop their talents. The typical response is to search for familiar Ph.D. names and check cover letters for impressive credits, but shove ev- Robert Newport, ery other manuscript right back into its accompanying SASE. M.D. Despite these depressing ob- servations, please don’t give up hope! There are still venues where Watch the Alcor Phoenix as the beginning writer can go for details unfold! editorial attention and reader rec- Artwork by Tim Hubley ognition. Look to the small press — it won’t catapult you to the wealth and celebrity you wish, but it will give you a reason to practice, and it may even intro- duce you to an editor who will chat about your submissions. Where do you find this “small press?” The latest edition of Writ- ers’ Market will give you several possibilities, but let me suggest a more obvious and immediate place to start sending your work: Cryonics Magazine! 2 Cryonics • 1st Qtr, 1999 Letters to the Editor RE: “Hamburger Helpers” by Charles Platt, in his/her interest to go this route if the “Cryonics” magazine, 4th Quarter greater cost of insurance is more than offset Sincerely, 1998 by lower dues. -
Optimization of Human Somatic Cells Cryopreservation Protocols by Polyethylene Glycols
ОРИГІНАЛЬНІ ДОСЛІДЖЕННЯ УДК 57.043:547.42:577.1 DOI 10.11603/mcch.2410-681X.2016.v0.i3.6933 O. M. Perepelytsina, A. P. Uhnivenko, D. P. Burlaka, S. V. Bezuhlyi, M. V. Sydorenko INSTITUTE FOR PROBLEMS OF CRYOBIOLOGY AND CRYOMEDICINE NAS UKRAINE, KYIV OPTIMIZATION OF HUMAN SOMATIC CELLS CRYOPRESERVATION PROTOCOLS BY POLYETHYLENE GLYCOLS Using of polyethylene glycol in optimization of human somatic cells of cryopreservation protocols was analyzed. Low molecular weight PEG as vitrification solution supplement exhibited a high cooling speed and provided cell survival in 200 % comparing with control. It allows recommending the use of low molecular weight PEG in vitrification environment for effective cell vitrification protocols. KEY WORDS: cryopreservation, vitrification, polyethylene glycol, cooling rate, cell survival, freezing protocols. INTRODUCTION. Vitrification is the solidification about 0.1–10 °C/sec (roughly 10–1,000 °C/min) are of a liquid brought about not by crystallization but sufficient to achieve vitrification [7]. by an extreme elevation in viscosity during cooling Cryoprotectants, or cryoprotective agents [1]. It is a widely applied alternative to standard slow (CPAs) have been extensively used for vitrification programmable freezing methods for cryopreservation [16, 17]. CPAs are chemicals which prevent cell because of the higher survival rates of cells after damage caused by cryopreservation [8]. Such thawing [2, 3]. Vitrification was first proposed in substances as alcohols, amides, oxides and poly- 1985 by Greg Fahy and William F. Rall [4] as a mers with corresponding functional groups can be method for cryopreserving complex tissues such effective CPAs. These chemicals increase the as whole organs. The motivation for vitrification was viscosity of aqueous solutions, reduce the freezing that conventional freeze preservation invariably point and lower the ice nucleation temperatures of destroyed organs by disrupting sensitive tissue aqueous solutions. -
Genes That Act Downstream of DAF-16 to Influence the Lifespan Of
articles Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans Coleen T. Murphy*, Steven A. McCarroll†, Cornelia I. Bargmann†, Andrew Fraser‡, Ravi S. Kamath‡, Julie Ahringer‡, Hao Li* & Cynthia Kenyon* * Department of Biochemistry and Biophysics, and † Department of Anatomy and Howard Hughes Medical Institute, University of California, San Francisco, California 94143-2200, USA ‡ Wellcome CRC Institute and Department of Genetics, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK ........................................................................................................................................................................................................................... Ageing is a fundamental, unsolved mystery in biology. DAF-16, a FOXO-family transcription factor, influences the rate of ageing of Caenorhabditis elegans in response to insulin/insulin-like growth factor 1 (IGF-I) signalling. Using DNA microarray analysis, we have found that DAF-16 affects expression of a set of genes during early adulthood, the time at which this pathway is known to control ageing. Here we find that many of these genes influence the ageing process. The insulin/IGF-I pathway functions cell non- autonomously to regulate lifespan, and our findings suggest that it signals other cells, at least in part, by feedback regulation of an insulin/IGF-I homologue. Furthermore, our findings suggest that the insulin/IGF-I pathway ultimately exerts its effect on lifespan by upregulating a wide variety of genes, including cellular stress-response, antimicrobial and metabolic genes, and by downregulating specific life-shortening genes. The recent discovery that the ageing process is regulated hormonally never been tested directly; for example, by asking whether stress by an evolutionarily conserved insulin/IGF-I signalling pathway1–3 response genes are required for the longevity of daf-2 mutants. -
From Here to Immortality: Anti-Aging Medicine
FromFrom HereHere toto Immortality:Immortaalitty: AAnti-AgingAnnntti-AAgging MMedicineedicine Anti-aging medicine is a $5 billion industry. Despite its critics, researchers are discovering that inter ventions designed to turn back time may prove to be more science than fiction. By Trudie Mitschang 14 BioSupply Trends Quarterly • October 2013 he symptoms are disturbing. Weight gain, muscle Shifting Attitudes Fuel a Booming Industry aches, fatigue and joint stiffness. Some experience The notion that aging requires treatment is based on a belief Thear ing loss and diminished eyesight. In time, both that becoming old is both undesirable and unattractive. In the memory and libido will lapse, while sagging skin and inconti - last several decades, aging has become synonymous with nence may also become problematic. It is a malady that begins dete rioration, while youth is increasingly revered and in one’s late 40 s, and currently 100 percent of baby boomers admired. Anti-aging medicine is a relatively new but thriving suffer from it. No one is immune and left untreated ; it always field driven by a baby- boomer generation fighting to preserve leads to death. A frightening new disease, virus or plague? No , its “forever young” façade. According to the market research it’s simply a fact of life , and it’s called aging. firm Global Industry Analysts, the boomer-fueled consumer The mythical fountain of youth has long been the subject of base will push the U.S. market for anti-aging products from folklore, and although it is both natural and inevitable, human about $80 billion now to more than $114 billion by 2015. -
SENS-Research-Foundation-2019
by the year 2050, cardiovascular an estimated 25-30 the american 85 percent of adults disease years and older age 85 or older remains the most population will suffer from common cause of 2 1 2 dementia. death in older adults. triple. THE CLOCK IS TICKING. By 2030, annual direct The estimated cost of medical costs associated dementia worldwide was 62% of Americans with cardiovascular $818 billion diseases in the united over age 65 have in 2015 and is states are expected to more than one expected to grow to rise to more than chronic condition.1 3 $2 trillion $818 billion. by 2030.1 References: (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732407/, (2) https://www.who.int/ageing/publications/global_health.pdf, (3) https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity sens research foundation board of directors Barbara Logan Kevin Perrott Bill Liao Chairperson Treasurer Secretary Michael Boocher Kevin Dewalt James O’Neill Jonathan Cain Michael Kope Frank Schuler 02 CONTENTS 2019 Annual Report 04 Letter From The CEO 06 Outreach & Fundraising 08 Finances 09 Donors erin ashford photography 14 Education 26 Investments 20 Conferences & Events 30 Research Advisory Board 23 Speaking Engagements 31 10 Years Of Research 24 Alliance 32 MitoSENS 34 LysoSENS 35 Extramural Research 38 Publications 39 Ways to Donate cover Photo (c) Mikhail Leonov - stock.adobe.com special 10th anniversary edition 03 FROM THE CEO It’s early 2009, and it’s very late at night. Aubrey, Jeff, Sarah, Kevin, and Mike are sitting around a large table covered in papers and half-empty food containers. -
Read Our New Annual Report
The seeds of a concept. The roots of an idea. The potential of a world free of age-related disease. Photo: Sherry Loeser Photography SENS Research Foundation Board of Directors Barbara Logan, Chair Bill Liao, Secretary Kevin Perrott, Treasurer Michael Boocher Jonathan Cain Kevin Dewalt Michael Kope Jim O’Neill Frank Schüler Sherry Loeser Photography 2 Contents CEO Letter (Jim O’Neill) 4 Finances 5 Donors 6 - 7 Fundraising & Conferences 8 - 9 Around the World with Aubrey de Grey 10 Outreach 11 Founding CEO Tribute & Underdog Pharmaceuticals 12 - 13 Investments 14 Welcome New Team Members 15 Education 16 - 17 Publications & Research Advisory Board 18 Research Summaries 19 - 22 Ways to Donate 23 The SRF Team Front row: Anne Corwin (Engineer/Editor), Amutha Boominathan (MitoSENS Group Lead), Alexandra Stolzing (VP of Research), Aubrey de Grey (Chief Science Officer), Jim O’Neill (CEO), Bhavna Dixit (Research Associate). Center row: Caitlin Lewis (Research Associate), Lisa Fabiny-Kiser (VP of Operations), Gary Abramson (Graphics), Maria Entraigues-Abramson (Global Outreach Coordinator), Jessica Lubke (Administrative Assistant). Back row: Tesfahun Dessale Admasu (Research Fellow), Amit Sharma (ImmunoSENS Group Lead), Michael Rae (Science Writer), Kelly Protzman (Executive Assistant). Not Pictured: Greg Chin (Director, SRF Education), Ben Zealley (Website/Research Assistant/ Deputy Editor) Photo: Sherry Loeser Photography, 2019 3 From the CEO At our 2013 conference at Queens College, Cambridge, I closed my talk by saying, “We should not rest until we make aging an absurdity.” We are now in a very different place. After a lot of patient explanation, publication of scientific results, conferences, and time, our community persuaded enough scientists of the feasibility of the damage repair approach to move SENS and SENS Research Foundation from the fringes of scientific respectability to the vanguard of a mainstream community of scientists developing medical therapies to tackle human aging.